Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo

Neuroscience

Volumn 97, Issue 2, 2000, Pages 243-251

  Wu, H Q ^a   Guidetti, P ^a   Goodman, J H ^b   Varasi, M ^c   Ceresoli Borroni, G ^a   Speciale, C ^c   Scharfman, H E ^b,d   Schwarcz, R ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b HELEN HAYES HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

3 Hydroxykynurenine; Excitotoxicity; Kynurenic acid; Kynurenine; Neuroprotection; NMDA receptor; Quinolinic acid

Indexed keywords

3 HYDROXYKYNURENINE; ANTICONVULSIVE AGENT; ENZYME INHIBITOR; EXCITOTOXIN; KYNURENIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENYLALANINE DERIVATIVE; PNU 156561; QUINOLINIC ACID; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HIPPOCAMPUS; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034049260     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00030-0     Document Type: Article

References (58)

1. Alger B.E., Teyler T.J. Long-term and short-term plasticity in the CA1, CA3 and dentate regions of the rat hippocampal slice. Brain Res. 110:1976;463-480.
2. Beagles K.E., Morrison P.F., Heyes M.P. Quinolinic acid in vivo synthesis rates, extracellular concentrations and intercompartmental distributions in normal and immune-activated brain as determined by multiple-isotope microdialysis. J. Neurochem. 70:1998;281-291.
3. Ceresoli-Borroni G., Dong H.X., Arends J.J.A., Fazzaro A., Ma D.D., He Y.Y., Hsu R., Schwarcz R., Jacquin M.F. Increased levels of 3-hydroxykynurenine (3-HK) after spinal contusion injury in rats. Soc. Neurosci. Abstr. 24:1998;290.8.
4. Chiarugi A., Carpenedo R., Molina M.T., Mattoli L., Pellicciari R., Moroni F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem. 65:1995;1176-1183.
5. Christensen H.N. Organic ion transport during seven decades: the amino acids. Biochim. Biophys. Acta. 779:1984;255-269.
6. Cozzi A., Carpenedo R., Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic damage: studies with m-nitrobenzoylalanine (mNBA) and with 3,4-dimethoxy-[N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. cerebr. Blood Flow Metab. 19:1999;771-777.
7. Czuczwar S.J., Meldrum B. Protection against chemically induced seizures by 2-amino-7-phosphonohepatanoic acid. Eur. J. Pharmac. 83:1982;335-338.
8. Eastman C.L., Guilarte T.R. Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 495:1989;225-231.
9. Eastman C.L., Guilarte T.R. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 15:1990;1101-1107.
10. Flanagan E.M., Erickson B., Viveros O.H., Chang S.Y., Reinhard J.F. Jr. Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis. J. Neurochem. 64:1995;1192-1196.
11. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56:1991;2007-2017.
12. Ganong A.H., Lanthorn T.H., Cotman C.W. Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Res. 273:1983;170-174.
13. Gill R., Woodruff G.N. The neuroprotective actions of kynurenic acid and MK-801 in gerbils are synergistic and not related to hypothermia. Eur. J. Pharmac. 176:1990;143-149.
14. 3H]kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J. Neurochem. 65:1995;2621-2632.
15. Guidetti P., Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11:1999;3857-3863.
16. Harris C.A., Miranda A.F., Tanguay J.J., Boegman R.J., Beninger R.J., Jhamandas K. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br. J. Pharmac. 124:1998;391-399.
17. Heyes M.P., Morrison P.F. Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J. Neurochem. 68:1997;280-288.
18. Heyes M.P., Quearry B.J. Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J. Chromatogr. 428:1988;340-344.
19. Heyes M.P., Saito K., Lackner A., Wiley C.A., Achim C.L., Markey S.P. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. Fedn Am. Socs. exp. Biol. J. 12:1998;881-896.
20. Heyes M.P., Swartz K.J., Markey S.P., Beal M.F. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease. Neurosci. Lett. 122:1991;265-269.
21. Hodgkins P., Schwarcz R. Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur. J. Neurosci. 10:1998;1986-1994.
22. Jauch D.A., Sethy V.H., Weick B.G., Chase T.N., Schwarcz R. Intravenous administration of L-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid. Neuropharmacology. 32:1993;467-472.
23. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
24. Joseph M.H., Baker H.F., Crow T.J., Riley G.J., Risby D. Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology. 62:1979;279-285.
25. Kessler M., Terramani T., Lynch G., Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J. Neurochem. 52:1989;1319-1328.
26. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 241:1988;835-837.
27. Miranda A.F., Boegman R.J., Beninger R.J., Jhamandas K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience. 78:1997;967-975.
28. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmac. 375:1999;87-100.
29. Moroni F., Russi P., Gallo-Mezo M.A., Moneti G., Pellicciari R. Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem. 57:1991;1630-1635.
30. Moroni F., Russi P., Lombardi G., Beni M., Carlà V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51:1988;177-180.
31. Nozaki K., Beal M.F. Neuroprotective effects of L-kynurenine on hypoxia-ischemic and NMDA lesions in neonatal rats. J. cerebr. Blood Flow Metab. 12:1992;400-407.
32. Okuda S., Nishiyama N., Saito H., Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. natn. Acad. Sci. U.S.A. 93:1996;12553-12558.
33. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 70:1998;299-307.
34. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmac. exp. Ther. 283:1997;1264-1275.
35. Pearson S.J., Reynolds G.P. Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathy. J. Chromatogr. 565:1991;436-440.
36. Pellicciari R., Natalini B., Costantino G., Mahmoud M.R., Mattoli L., Sadeghpour B.M., Moroni F., Chiarugi A., Carpenedo R. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J. med. Chem. 37:1994;647-655.
37. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247:1982;184-187.
38. Reinhard J.F. Jr., Erickson J.B., Flanagan E.M. Quinolinic acid in neurological disease: opportunities for novel drug discovery. Adv. Pharmac. 30:1994;85-127.
39. Reynolds G.P., Pearson S.J. Increased brain 3-hydroxykynurenine in Huntington's disease. Lancet. 2:1989;979-980.
40. Röver S., Cesura A.M., Huguenin P., Kettler R., Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. med. Chem. 40:1997;4375-4385.
41. Saito K., Markey S.P., Heyes M.P. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience. 51:1992;25-39.
42. Santamaría A., Ríos C., Solís-Hernández F., Ordaz-Moreno J., González-Reynoso L., Altagracia M., Kravzov J. Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology. 35:1996;23-28.
43. Scharfman H.E., Goodman J.H. Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro. Neuroscience. 86:1998;751-764.
44. Schwarcz R., Köhler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 38:1983;85-90.
45. Schwarcz R., Whetsell W.O. Jr., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 218:1983;316-318.
46. Schwarcz R., Young S. N. and Brown R. R. (1991) Kynurenine and Serotonin Pathways: Progress in Tryptophan Research. Plenum, New York.
47. Speciale C., Cini M., Wu H.-Q., Salvati P., Schwarcz R., Molinari A. and Varasi M. (1996a) Kynurenic acid-enhancing and anti-ischemic effects of the potent kynurenine 3-hydroxylase inhibitor FCE 28833 in rodents. In Recent Advances in Tryptophan Research, pp. 221-227. Plenum, New York.
48. +-independent transporter of neutral amino acids in astrocytes. J. Neurosci. 9:1989;2066-2072.
49. Speciale C., Wu H.-Q., Cini M., Marconi M., Varasi M., Schwarcz R. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmac. 315:1996;263-267.
50. Speciale C., Wu H.-Q., Gramsbergen J.B.P., Turski W.A., Ungerstedt U., Schwarcz R. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid. Neurosci. Lett. 116:1990;198-203.
51. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmac. Rev. 45:1993;309-379.
52. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmac. 72:1981;411-412.
53. Swartz K.J., During M.J., Freese A., Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10:1990;2965-2973.
54. Taguchi H.T. Separation and determination of nicotinic acid related compounds by HPLC and its application. Vitamins. 64:1990;19-25.
55. Turski W.A., Nakamura M., Todd W.P., Carpenter B.K., Whetsell W.O. Jr., Schwarcz R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res. 454:1988;164-169.
56. Ubbink J.B., Vermaak W.J.H., Bissbort S.H. High-performance liquid chromatographic assay of human lymphocyte kynureninase activity levels. J. Chromatogr. 566:1991;369-375.
57. Varasi M., Speciale C., Cini M., Marconi M., Breda M., Giordani A., Bormetti R., Post C. FCE 28833A, a novel kynurenine 3-hydroxylase inhibitor: in vitro and in vivo characterization of the two enantiomers. Soc. Neurosci. Abstr. 22:1996;608.10.
58. Vécsei L., Miller J., MacGarvey U., Beal M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull. 28:1992;233-238.